clinical trial · NCT04471727
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·phase2·active not recruiting·n = 232
Small-Cell Lung CancerNeuroendocrine CarcinomaGocatamigAtezolizumabIfinatamab Deruxtecan (I-DXd)
brief summary
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
started
Dec 14, 2020
primary completion
Jan 28, 2028
completion
Jan 28, 2028
last updated
Feb 24, 2026
official title
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol